Somerville Kurt F Has $20.56 Million Stake in Abbott Laboratories $ABT

Somerville Kurt F cut its position in shares of Abbott Laboratories (NYSE:ABT) by 3.2% in the third quarter, Holdings Channel.com reports. The firm owned 153,512 shares of the healthcare product maker’s stock after selling 5,145 shares during the quarter. Abbott Laboratories comprises approximately 3.4% of Somerville Kurt F’s investment portfolio, making the stock its 9th biggest position. Somerville Kurt F’s holdings in Abbott Laboratories were worth $20,561,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently bought and sold shares of the business. Clear Creek Financial Management LLC increased its stake in Abbott Laboratories by 5.2% in the third quarter. Clear Creek Financial Management LLC now owns 5,269 shares of the healthcare product maker’s stock worth $706,000 after purchasing an additional 260 shares during the period. King Luther Capital Management Corp grew its holdings in shares of Abbott Laboratories by 0.5% in the third quarter. King Luther Capital Management Corp now owns 1,435,459 shares of the healthcare product maker’s stock worth $192,265,000 after purchasing an additional 6,696 shares during the last quarter. Harold Davidson & Associates Inc. increased its stake in Abbott Laboratories by 27.3% in the 3rd quarter. Harold Davidson & Associates Inc. now owns 10,945 shares of the healthcare product maker’s stock worth $1,466,000 after buying an additional 2,347 shares during the period. MRP Capital Investments LLC bought a new stake in Abbott Laboratories during the 3rd quarter valued at about $101,000. Finally, Synovus Financial Corp boosted its position in Abbott Laboratories by 2.3% in the 3rd quarter. Synovus Financial Corp now owns 164,218 shares of the healthcare product maker’s stock valued at $21,997,000 after buying an additional 3,718 shares during the period. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Insider Transactions at Abbott Laboratories

In other Abbott Laboratories news, Director Daniel J. Starks bought 10,000 shares of the business’s stock in a transaction on Wednesday, February 4th. The stock was bought at an average price of $108.73 per share, for a total transaction of $1,087,300.00. Following the completion of the transaction, the director owned 6,738,817 shares in the company, valued at approximately $732,711,572.41. The trade was a 0.15% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 0.46% of the company’s stock.

Abbott Laboratories Stock Performance

Shares of ABT traded down $0.26 during mid-day trading on Friday, reaching $111.93. The company had a trading volume of 587,957 shares, compared to its average volume of 10,988,143. Abbott Laboratories has a 52-week low of $105.27 and a 52-week high of $141.23. The company has a quick ratio of 1.24, a current ratio of 1.70 and a debt-to-equity ratio of 0.23. The stock has a market capitalization of $194.64 billion, a P/E ratio of 30.09, a PEG ratio of 1.80 and a beta of 0.75. The stock has a 50 day moving average of $118.72 and a two-hundred day moving average of $126.00.

Abbott Laboratories (NYSE:ABT) last posted its earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 EPS for the quarter, meeting analysts’ consensus estimates of $1.50. The company had revenue of $11.46 billion for the quarter, compared to analysts’ expectations of $11.80 billion. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.94%. Abbott Laboratories’s revenue for the quarter was up 4.4% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.34 earnings per share. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. On average, analysts expect that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, February 13th. Shareholders of record on Thursday, January 15th were issued a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a yield of 2.3%. This is a boost from Abbott Laboratories’s previous quarterly dividend of $0.59. The ex-dividend date of this dividend was Thursday, January 15th. Abbott Laboratories’s dividend payout ratio is 67.74%.

Analyst Ratings Changes

A number of analysts recently issued reports on ABT shares. Sanford C. Bernstein lowered their price target on Abbott Laboratories from $154.00 to $125.00 and set an “outperform” rating for the company in a report on Friday, January 23rd. Citigroup decreased their target price on Abbott Laboratories from $155.00 to $140.00 and set a “buy” rating for the company in a research report on Friday, January 23rd. William Blair raised Abbott Laboratories to a “strong-buy” rating in a research report on Thursday, November 20th. Argus decreased their price objective on Abbott Laboratories from $150.00 to $140.00 in a report on Tuesday, January 27th. Finally, Evercore dropped their target price on shares of Abbott Laboratories from $144.00 to $138.00 and set an “outperform” rating on the stock in a report on Friday, January 23rd. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $137.05.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.